Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Oyster Point Pharma, Inc. OYST NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
27/100
0/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Oyster Point Pharma, Inc. (OYST) is a Biotechnology company in the Healthcare sector, currently trading at $11.17. It has a SharesGrow Score of 26/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $25M, +0%/yr average growth. Net income is $104M (loss), growing at -93.1%/yr. Net profit margin is -425.4% (negative). Gross margin is 93.8% (+0 pp trend).

Balance sheet: total debt is $93M against $100M equity (Debt-to-Equity (D/E) ratio 0.93, moderate). Current ratio is 7.47 (strong liquidity). Debt-to-assets is 41.7%. Total assets: $223M.

Analyst outlook: 3 / 6 analysts rate OYST as buy (50%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 46/100 (Partial), Future 40/100 (Partial), Income 10/100 (Fail).

OYST SharesGrow Score Overview

32/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 40/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — OYST

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
OYST: +0%/yr revenue is, -93.1%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet OYST: Debt-to-Equity (D/E) ratio 0.93 (moderate), Current ratio is 7.47 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
OYST: Gross margin is 93.8% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
40/100
Analyst outlook: 3 / 6 analysts rate OYST as buy (50%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
OYST: Net profit margin is -425.4%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range3.46-13.45
Volume2.09M
Avg Volume (30D)417.56K
Beta (1Y)0.00
Share Statistics
EPS (TTM)-4.01
Shares Outstanding$26.04M
IPO Date2019-10-31
Employees303
CEOJeffrey Nau
Financial Highlights & Ratios
Revenue (TTM)$24.54M
Gross Profit$23.01M
EBITDA$-96.78M
Net Income$-104.39M
Operating Income$-96.93M
Total Cash$193.37M
Total Debt$92.73M
Net Debt$-100.64M
Total Assets$222.62M
Price / Earnings (P/E)-2.8
Analyst Forecast
Rating ConsensusBuy
Analysts Covering6
Buy 50% Hold 50% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS69242L1061

Price Chart

Track all markets on TradingView
OYST
Oyster Point Pharma, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
3.46 52WK RANGE 13.45

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message